KX2-391

• Description:

  KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Weight:

  431.53

• Molecular Formula:

  C26H29N3O3

• Notes:

  Research use only, not for human use.

• Receptor:

  Src (Hep 3B) | Src (Hep G2) | Src (HuH7) | Src (PLC/PRF/5)

• CAS Number:

  897016-82-9